Dr Reddy’s De Vré On Momentum In US Biosimilars Market, Interchangeability

The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.

Raymond De Vre — Raymond De Vré, Dr Reddy’s Biologics Business Unit Global Head

An estimated $75bn worth of blockbuster biologic products are expected to be exposed to biosimilar competition by 2025 and Indian firms like Dr. Reddy's Laboratories Ltd. are upbeat about emerging prospects in the US, amid signs of improving adoption of such products and coverage by insurers and payers.

The strong performance of biosimilar pegfilgrastim in the US, especially Coherus BioSciences Inc.’s Udenyca (pegfilgrastim-cbqv), with “rapid and high...